Table 1

Articles eligible for this systematic review

First author, YOPCountrySample sizeDisease severityATTAgeFemale (%)Follow-up
Randomised controlled trials
 Cassar, 200645 UK67R 1–3 w EVRA w C or PLBMn 66
(R: 43–80)
15 (22)1 M
 Haile, 202232 Sweden105R 1–3 w EVR/SVRAny ATTMd 72
(IQR: 69–77)
54 (52)1.5 Y
 Hess, 202230 Multiple6564R 1–6 w EVR/SVRASA w PLB or DOACMn 68
(IQR: 60–76)
1704 (26)Md 28 M (IQR: 22–34)
 Jivegård, 200548 Sweden281R 4–6ASA w PLB or LMWHMn 74
(SD:9)
126 (45)3 M
 Qvist, 201931 Denmark2051R 0–6 w/o EVR/SVRAny ATTMn 70
(SD: 2.9)
0 (0)5 Y
 Weissler, 202229 Multiple13 842R 1–6 w/o EVR/SVRC or TMn 67
(IQR: 59–75)
3884 (28)30 M (up to 42 M)
Prospective trials
 Ferreira, 201046 Spain194NRAny APTMn 64
(SD: 11.2)
43 (22)1 Y
 Kremers, 2023 49 Netherlands246R 1–4Any APTMn 69
(SD: 9.2)
105 (43)1 Y
Retrospective studies
 Halle, 201736 USA100R 1–6 w/o EVR/SVRAny APTMn 64
(SD: 9.5)
42 (42)NR
 Wawruch, 202133 Slovak Republic9178R 0–6 w/o EVR/SVRAny APTMn 755285 (58)5 Y
Total32 62811 258 (35)
  • ±, SD deviation; (), percentage; A, acetylsalicylic acid; APT, antiplatelet therapy; ATT, antithrombotic therapy; C, clopidogrel; DOAC, direct-acting oral anticoagulant; EVR, endovascular revascularisation; LMWH, low molecule weight heparin; M, months; Md, median; Mn, mean; NR, not reported; PLB, placebo; R, Rutherford classification; R, range; SVR, surgical/open revascularisation; w, with; w/o, with or without; Y, years; YOP, year of publication.